|Articles|February 1, 2002

New Approaches to the Treatment of Migraine: Clinical and Economic Impact
Volume 8
Issue 3 Suppl

Migraine: Diagnosis, Management, and New Treatment Options

Author(s)R. Michael Gallagher, DO, F. Michael Cutrer, MD

Download PDF: Migraine: Diagnosis, Management, and New Treatment Options

Articles in this issue

over 24 years ago

Article

Participating Faculty

over 24 years ago

Article

Introduction

over 24 years ago

Article

Almotriptan: A Review of Pharmacology, Clinical Efficacy, and Tolerability

over 24 years ago

Article

Economic Comparison of Oral Triptans for Management of Acute Migraine: Implications for Managed Care

over 24 years ago

Article

Health Outcomes Evaluations: Estimating the Impact of Almotriptan in Managed Care Settings

over 24 years ago

Article

Almotriptan Versus Sumatriptan in Migraine Treatment: Direct Medical Costs of Managing Adverse Chest Symptoms

over 24 years ago

Article

Cost Savings in Migraine Associated with Less Chest Pain on New Triptan Therapy

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

ByOnur Baser, PhD, MS,Heidi C. Waters, PhD,Nehir Yapar, BS,Gabriela Samayoa, MD, MPH,Xue Han, PhD,Deborah Freedman, MBA,Lauren Isenman, MPH,Rashmi Patel, MD, PhD

June 12th 2026

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

ByJason Bartock, MD,Adam Green, MD,Raquel Nahra, MD,Amy Bordogna, MD,Amir Davoodi, MD,Jean-Sebastien Rachoin, MD

June 11th 2026

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Migraine: Diagnosis, Management, and New Treatment Options

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

ATTR-CM Incidence, Prevalence Rose Sharply in the US

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Natera's Moshkevich Discusses TOMR Approach and the Future of MRD-Guided Care

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Migraine: Diagnosis, Management, and New Treatment Options

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

ATTR-CM Incidence, Prevalence Rose Sharply in the US

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Natera's Moshkevich Discusses TOMR Approach and the Future of MRD-Guided Care